US Tests Anti Aging Drug Regimen

More than one in 10 Americans takes a GLP-1 medication for weight loss, and as more people take these medications, the numbers of older adults taking them are set to skyrocket. The Trump administration recently launched the Medicare GLP-1 Bridge program, which sets the cost of three weight-loss medications, including Wegovy and Zepbound, at $50 a month.

This news may benefit the estimated 38.9 percent of adults aged 60 and up in the U.S. who are living with obesity. However, it could also supercharge an ongoing and risky experiment in growing old on weight-loss drugs.

For years, clinicians have had few good options to safely treat obesity in older adults. While GLP-1s are now approved for weight loss, the evidence supporting their use in the age-60-and-older population is limited.

Someone in their 70s may benefit as much from weight loss as a person in their 30s but may respond very differently to these drugs’ side effects; experts advise that we simply don’t have enough evidence yet to make informed conclusions.

Ruchi Gaba, an associate professor of endocrinology at Baylor College of Medicine, notes that “eligibility doesn’t mean benefit automatically” and that clinicians must individualize treatment.

Older adults are underrepresented in the clinical trials for GLP-1 drugs, with only about one in 10 participants in early trials being age 65 or older, according to Alissa Chen, a primary care physician and researcher at the Yale School of Medicine.

Older adults are more heterogeneous than people in younger age groups in terms of chronic conditions and multiple medications, which can pose challenges with both prescriptions and side effects.

Chen says that clinicians need to be more critical about who they start on these medications and think about the potential benefits and risks, including the impact on chronic conditions and overall health.

GLP-1 drugs work by mimicking the glucagonlike peptide 1 hormone, which stimulates insulin secretion and slows gastric emptying, creating a prolonged feeling of fullness that drives weight loss.

However, these drugs can also create cascading risks, including slow gastric emptying, which can worsen constipation, nausea, and vomiting, and increase the risk of dehydration and orthostatic hypotension.

Gaba notes that GLP-1s can also cause lean muscle loss, which can make older adults more at risk of serious injury if they fall.

Additionally, older patients may respond to medications differently than their younger counterparts due to their body composition and reduced liver and kidney function.

Analyses to date show that GLP-1 drugs are associated with fewer cardiovascular events and lower all-cause mortality in older adults, but there is no direct evidence that they extend lifespan.

They must individualize treatment for each patient.

It is essential to consider the potential benefits and risks of GLP-1 medications for older adults, including the impact on chronic conditions and overall health.

Researchers like Chen and Gaba are working to better understand the effects of these medications on older adults, which will help inform treatment decisions.

The Medicare GLP-1 Bridge program may provide temporary relief for some patients, but it is key to consider the long-term effects of these medications and develop strategies for sustainable weight loss and overall health improvement.